Amgen and Allergan announced on Thursday that the European Commission has granted a marketing authorization to Mvasi, a biosimilar bevacizumab referencing Avastin, for the treatment of certain cancers.
Amgen and Allergan announced on Thursday that the European Commission (EC) has granted a marketing authorization to Mvasi, a biosimilar bevacizumab referencing Avastin, for the treatment of certain cancers.
The EC approval grants a centralized marketing authorization for the drug, with unified labeling, in the 28 members of the European Union. European Economic Area nations (Norway, Iceland, and Liechtenstein) will make regulatory decisions concerning the drug based on the EC’s approval. The marketing authorization follows a positive opinion on the biosimilar granted by the European Medicines Agency’s Committee for Medicinal Products for Human Use granted in November 2017.
"The European Commission's approval of Mvasi marks a significant milestone for both Amgen and the oncology community, providing a biosimilar for a medicine which is used across multiple types of cancer," said Sean E. Harper, MD, executive vice president of research and development at Amgen, in a statement. "Mvasi is the first targeted cancer biosimilar from Amgen's portfolio approved in Europe, underscoring our commitment to delivering high-quality medicines that address some of the most serious illnesses."
European regulatory clearance for Mvasi follows the FDA’s approval of the drug in September 2017, based on a comprehensive data package including analytical, pharmacokinetic, and clinical data that demonstrated that the biosimilar and its reference are highly similar, with no clinically meaningful differences in terms of efficacy, safety, and immunogenicity. Clinical data presented to the FDA included results of a phase 3 study of Mvasi in patients with non—small-cell lung cancer.
Despite these 2 approvals, the timing of Mvasi’s launch remains unclear. In the United States, ongoing patent litigation continues to delay commercial availability of the biosimilar; Genentech, maker of the reference Avastin, recently sued Amgen over Mvasi in a Delaware court, saying that the biosimilar developer did not properly exchange information related to the drug as required under the Biologics Price Competition and Innovation Act, and that Amgen refused to negotiate the scope of litigation concerning alleged patent infringement. Meanwhile, Amgen has filed suit in a California court, seeking a judgment that Mvasi did not and will not infringe on 27 patents covering the reference Avastin.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.